---
title: "Aytu Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary"
date: "2025-02-13 05:50:49"
summary: "Aytu Biopharma Inc reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -4 cents. The lone analyst forecast for the quarter was for a loss of 28 cents per share...."
categories:
  - "Reuters"
lang:
  - "en"
translations:
  - "en"
tags:
  - "Reuters"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

* Aytu Biopharma Inc reported a quarterly adjusted loss of 26 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -4 cents. The lone analyst forecast for the quarter was for a loss of 28 cents per share.
* Revenue fell 29.3% to $16.22 million from a year ago; analysts expected $15.55 million.
* Aytu Biopharma Inc's reported EPS for the quarter was 9 cents​.
* The company reported quarterly net income of $788 thousand.
* Aytu Biopharma Inc shares had fallen by 16.5% this quarter.

FORECAST CHANGES

* The mean earnings estimate of analysts had fallen by about 366.7% in the last three months.​
* In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Aytu Biopharma Inc is $8.00

This summary was machine generated from LSEG data February 12 at 09:50 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact [RefinitivNewsSupport@thomsonreuters.com](http://mailto:RefinitivNewsSupport@thomsonreuters.com))

| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| --- | --- | --- | --- |
| Dec. 31 2024 | -0.28 | -0.26 | Beat |
| Sep. 30 2024 | -0.34 | 0.44 | Beat |
| Jun. 30 2024 | -0.45 | -0.82 | Missed |
| Mar. 31 2024 | -0.64 | -0.52 | Beat |

[Reuters](https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3P32H8:0-aytu-biopharma-inc-reports-results-for-the-quarter-ended-december-31-earnings-summary/)
